SmallCaps
ASX:IDTPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals

IDT Australia Ltd

$0.034
Day Range
$0.033 – $0.034
52 Week Range
$0.030 – $0.100
Volume
151.05K
Avg Volume (10D)
196.89K
Market Cap
$14.53M
Price Chart
Market Statistics
Open$0.034
Previous Close$0.034
Day High$0.034
Day Low$0.033
52 Week High$0.100
52 Week Low$0.030
Valuation
Market Cap14.53M
Shares Outstanding427.43M
Price to Book0.72
Trading Activity
Volume151.05K
Value Traded5.11K
Bid$0.034 × 95,465
Ask$0.035 × 88,786
Performance
1 Day0.00%
5 Day6.25%
13 Week-15.00%
52 Week-64.95%
YTD-33.33%
Technical Indicators
RSI (14)50.71
50-Day SMA$0.035
200-Day SMA$0.047
Latest News
IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy
Biotechnology

IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy

IDT Australia (ASX: IDT) reports improving six-month ops under a new leadership team and realignment strategy; revenue up 20% to $8.4m, EBITDA losses narrowed.

IDT Australia to pioneer national ADC manufacturing with Victorian government grant
Biotechnology

IDT Australia to pioneer national ADC manufacturing with Victorian government grant

Pharmaceutical manufacturing company IDT Australia (ASX: IDT) has been awarded a grant by the Victoria state government to partly fund the establishment of Australia’s first current good manufacturing practice antibody-drug-conjugate (ADC) manufacturing facility. The grant, provided by the Victorian Industry Investment Fund stream of the Victorian Jobs and Investment Fund, will support IDT Australia’s new […]

Cann to supply medicinal cannabis products to EU and UK, IDT will manufacture
Industrials & Juniors

Cann to supply medicinal cannabis products to EU and UK, IDT will manufacture

Australian cannabis developer Cann Group (ASX: CAN) has signed two agreements for the supply of medicinal cannabis-formulated oil and dried flower products to markets in the United Kingdom and European Union. The first deal is with UK-based Astral Health for the supply of oils including high THC (tetrahydrocannabinol), high CBD (cannabidiol) and a balanced formulation […]

Cann Group and IDT Australia move closer to bringing medicinal cannabis products to market
Biotechnology

Cann Group and IDT Australia move closer to bringing medicinal cannabis products to market

Cann Group (ASX: CAN) and IDT Australia (ASX: IDT) are closer to producing their first medicinal cannabis products with GMP extraction activities now underway. Once extracted, the resin will be used as an active pharmaceutical ingredient for either purchase or to produce GMP medicinal cannabis oil products at IDT’s facilities. The next step for the […]